Grifols, S.A.
GRFS
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalentā¦ read more
Healthcare
Drug ManufacturersāGeneral
14 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$9.49
Price+0.11%
$0.01
1Y
Price
Market Cap
$8.028b
Mid
Price/Earnings 3y Avg5y Avg
14.8x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in EUR.+24.5%
EBITDA Margin+6.8%
Net Profit Margin+13.7%
Free Cash Flow Margin+24.5%
EBITDA Margin+6.8%
Net Profit Margin+13.7%
Free Cash Flow MarginRevenue
$7.518b
+4.2%
1y CAGR+7.4%
3y CAGR+11.3%
5y CAGREarnings
$372.721m
+137.5%
1y CAGR+110.4%
3y CAGR+82.3%
5y CAGREPS
$0.55
+139.1%
1y CAGR+74.6%
3y CAGR+59.6%
5y CAGRBook Value
$7.572b
$19.917b
Assets$12.345b
Liabilities$9.719b
DebtDebt to Assets
48.8%
6.3x
Debt to EBITDAFree Cash Flow
$851.185m
+60.4%
1y CAGR+272.0%
3y CAGR+151.4%
5y CAGRNo items found.
Press Releases
Statements and updates from the company